Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.

BMC research notes - 20 Apr 2024

Seman Zahidah Abu, Ahid Fadly, Kamaluddin Nor Rizan, Sahid Ermi Neiza Mohd, Esa Ezalia, Said Siti Shahrum Muhamed, Azman Norazlina, Mat Wan Khairull Dhalila Wan, Abdullah Julia, Ali Nurul Aqilah, Khalid Mohd Khairul Nizam Mohd, Yusoff Yuslina Mat

Abstract excerpt

OBJECTIVE: Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. This study aimed to detect BCR::ABL1 KD mutations in CML patients with treatment resistance and assess the concordance between NGS (next generation sequencing) and Sanger...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38643202
DOI: 10.1186/s13104-024-06772-1
PMCID: PMC11031984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.PMID 38643202Read ↗

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Mutations in the BCR‑ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosisSemantic proximity Read ↗

Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort.Semantic proximity Read ↗

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.Semantic proximity Read ↗

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcomeSemantic proximity Read ↗

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read ↗

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.Semantic proximity Read ↗

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.Semantic proximity Read ↗

[Clinical Value of Detecting ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Based on High-Throughput Sequencing Technology].Semantic proximity Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.